Please ensure Javascript is enabled for purposes of website accessibility

Why Biogen Stock Is Sinking Today

By Keith Speights – Apr 22, 2020 at 10:18AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The biotech's Q1 update brought some unwelcome news.

What happened

Shares of Biogen (BIIB 0.22%) were sinking 10.5% as of 10:59 a.m. EDT on Wednesday. The big drop came after the biotech announced in its first-quarter earnings update that it was delaying the filing for U.S. regulatory approval of aducanumab in treating Alzheimer's disease.

Biogen stated in October 2019 that it planned to file for approval of aducanumab in early 2020. Now, however, the company expects to complete its Food and Drug Administration filing in the third quarter of this year.

So what

Any pipeline or regulatory delay is bad news for a biotech stock. But the postponement of filing for approval of aducanumab is especially concerning for Biogen. Much of the company's potential growth prospects ride on success for the experimental Alzheimer's drug.

Hand holding a blue figure of a human head with a jigsaw cutout with another hand holding a red jigsaw puzzle piece that fits into the opening

Image source: Getty Images.

Biogen's multiple sclerosis franchise is losing momentum, and stiff competition for its spinal muscular atrophy drug Spinraza could be only months away if Roche Holdings' risdiplam wins FDA approval. Biogen sorely needs a win for aducanumab. 

It's a wonder that success is even still a possibility for the Alzheimer's drug. Biogen seemingly threw in the towel in March 2019 after the drug flopped in a late-stage clinical study. However, the biotech came back several months later and said that additional analysis showed that aducanumab reduced levels of amyloid in the brain and reduced clinical decline in patients with Alzheimer's disease.

Now what

There's now a longer waiting game for investors than there was before to see what will happen with aducanumab. The delay in regulatory filing doesn't necessarily lower the chances of FDA approval. But it definitely underscores the high level of risk that Biogen faces.

Keith Speights has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Biogen. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Biogen Inc. Stock Quote
Biogen Inc.
BIIB
$262.26 (0.22%) $0.57
Roche Holding Ltd. (ADR) Stock Quote
Roche Holding Ltd. (ADR)
RHHBY
$41.05 (-1.63%) $0.68

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
339%
 
S&P 500 Returns
109%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/06/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.